Amarin +4.4% AH on U.S. Vascepa co-promotion deal

Amarin (AMRN) is partnering with Japan's Kowa Pharmaceuticals to co-promote Vascepa in the U.S.

Kowa's 250 U.S. sales reps will join Amarin's 130 sales reps in selling Vascepa. Kowa will be paid a co-promotion fee based on a percentage of Vascepa's gross margins "that increase during the agreement's term, from the high single digits in 2014 to the low twenty percent levels in 2018, subject to certain adjustments."

The initial deal term runs through 2018.

More on Vascepa

From other sites
Comments (2)
  • Bob 88
    , contributor
    Comments (50) | Send Message
    Is this partnering good news or bad news? I cannot tell anymore!
    1 Apr 2014, 12:26 AM Reply Like
  • mitrado
    , contributor
    Comments (2033) | Send Message
    I don't care anymore. I bought some $AMRN shares very "cheap" (~ $10) and I've decided to accumulate more around $2. Now I'll just wait... and wait... and wait.


    I've learnt my lesson with this stock: no more biostocks for me, only dividend shares from now on. And I won't ever buy shares of a company that Adam Fraudstein obsesses about. Like $SRPT. :-P
    1 Apr 2014, 07:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs